A Study to Evaluate ALN-AGT01 RVR in Adult Healthy Volunteers
NCT ID: NCT06675565
Last Updated: 2025-09-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
42 participants
INTERVENTIONAL
2024-11-05
2025-09-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phase 1 Single and Multiple Ascending Dose of LTG-321 in Healthy Participants
NCT07110610
A Phase 1 Single and Multiple Ascending Dose Study of LTG-001 Administered Orally in Healthy Participants
NCT06049095
A Study of a Single Dose of ALXN1210 in Healthy Participants
NCT05288660
Study to Evaluate Safety, Tolerability, PK and PD of ALXN1007 in Healthy Subjects
NCT01454986
Adult Healthy Volunteers Study to Evaluate ALPN-101 Safety
NCT03748836
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ALN-AGT01 RVR
Participants will be administered a single dose of ALN-AGT01 RVR.
ALN-AGT01 RVR
ALN-AGT01 RVR will be administered subcutaneously (SC)
Placebo
Participants will be administered a single dose of placebo.
Placebo
Placebo will be administered SC
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ALN-AGT01 RVR
ALN-AGT01 RVR will be administered subcutaneously (SC)
Placebo
Placebo will be administered SC
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Has a body mass index ≥18 kg/m\^2 and ≤28 kg/m\^2
Exclusion Criteria
* Has known human immunodeficiency virus infection; or known current or chronic hepatitis C virus or hepatitis B virus infection
* Has an estimated glomerular filtration rate (eGFR) of \<90 mL/min/1.73m\^2 at screening
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alnylam Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinical Trial Site
Montreal, , Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ALN-AGT01 RVR-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.